Understanding how certain genes affect T cell growth in cancer treatment
Decoding the epigenetic landscape that delineates T cell homeostatic proliferation from uncontrolled growth”
['FUNDING_CAREER'] · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · NIH-10871886
This study is looking at how certain changes in genes affect T cells, which are important for fighting cancer, and it aims to find ways to make cancer treatments work better for patients.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (nih funded) |
| Locations | 1 site (MEMPHIS, UNITED STATES) |
| Trial ID | NIH-10871886 on ClinicalTrials.gov |
What this research studies
This research investigates the epigenetic changes that lead to T cell exhaustion, a major barrier in cancer immunotherapy. By focusing on specific genes like DNMT3A and TET2, the study aims to understand how these changes impact the ability of T cells to proliferate effectively. The approach involves analyzing how these genetic factors influence T cell behavior in the context of therapies such as CAR T cell treatment and PD-1 blockade. Patients may benefit from insights that could enhance the effectiveness of their cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing or considering T cell-based immunotherapies for cancer.
Not a fit: Patients who do not have cancer or are not receiving T cell-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer immunotherapy strategies that enhance T cell function and proliferation.
How similar studies have performed: Previous research has shown promising results in understanding T cell behavior through similar genetic investigations, indicating potential for success in this area.
Where this research is happening
MEMPHIS, UNITED STATES
- ST. JUDE CHILDREN'S RESEARCH HOSPITAL — MEMPHIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZEBLEY, CAITLIN — ST. JUDE CHILDREN'S RESEARCH HOSPITAL
- Study coordinator: ZEBLEY, CAITLIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy